Inhibition of Human Oral Squamous Cell Carcinoma Proliferation and Migration by Prodrug-activating Suicide Gene Therapies

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2023 Feb 10

PMID 36761002

Authors

Naining Xu

Honglei Tian

Chun Po Fung

Yuntao Lin

Yuling Chen

Guang Zhu

Yuehong Shen

Chuanbin Guo

Hongyu Yang

Affiliations

Soon will be listed here.

Abstract

Head and neck squamous cell carcinoma (HNSCC), which originates from mucosal epithelium in the oral cavity, pharynx and larynx, is the sixth most common malignancy in the world. The prognosis of HNSCC is not satisfactory due to metastasis, resulting in 5-year survival rates ranging from 65.9 to 67.2%. Previously, we developed a method to evaluate the effect prodrug-activating suicide gene (PA-SG) therapy on the proliferation of HNSCC. The present study investigated PA-SG therapy on metastatic HNSCC by wound-healing assay and our previously established method. HSC-3 cells with stable expression of suicide genes thymidine kinase (TK) or cytosine deaminase (CD) were treated with prodrugs ganciclovir (GCV) or 5-fluorocytosine (5-FC), respectively. Both GCV and 5-FC inhibited HSC-3 proliferation while the bystander effect of CD/5-FC was greater compared with that of TK/GCV. GCV showed a greater anti-migration effect compared with that of 5-FC. To the best of our knowledge, the present study is the first to evaluate the anti-migratory and anti-proliferative effects of PA-SG therapies on metastatic HNSCC. This may also serve as a general method to quantify other types of PA-SC therapy. The present results demonstrated that PA-SG therapy is a promising treatment for anti-metastatic HNSCC therapy development.

References

Bonneton C, Sibarita J, Thiery J . Relationship between cell migration and cell cycle during the initiation of epithelial to fibroblastoid transition. Cell Motil Cytoskeleton. 1999; 43(4):288-95. DOI: 10.1002/(SICI)1097-0169(1999)43:4<288::AID-CM2>3.0.CO;2-Y. View

Bali A, Bali D, Sharma A . An overview of gene therapy in head and neck cancer. Indian J Hum Genet. 2013; 19(3):282-90. PMC: 3841551. DOI: 10.4103/0971-6866.120811. View

Gao J, Yan Q, Liu S, Yang X . Knockdown of EpCAM enhances the chemosensitivity of breast cancer cells to 5-fluorouracil by downregulating the antiapoptotic factor Bcl-2. PLoS One. 2014; 9(7):e102590. PMC: 4097402. DOI: 10.1371/journal.pone.0102590. View

Eagle H . Propagation in a fluid medium of a human epidermoid carcinoma, strain KB. Proc Soc Exp Biol Med. 1955; 89(3):362-4. DOI: 10.3181/00379727-89-21811. View

Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S . Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11):1116-27. DOI: 10.1056/NEJMoa0802656. View

Kondo S, Aso K . Establishment of a cell line of human skin squamous cell carcinoma in vitro. Br J Dermatol. 1981; 105(2):125-32. DOI: 10.1111/j.1365-2133.1981.tb01196.x. View

Cong L, Ran F, Cox D, Lin S, Barretto R, Habib N . Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339(6121):819-23. PMC: 3795411. DOI: 10.1126/science.1231143. View

Bonner J, Harari P, Giralt J, Azarnia N, Shin D, Cohen R . Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-78. DOI: 10.1056/NEJMoa053422. View

Liang L, Bi W, Chen W, Lin Y, Tian Y . Combination of MPPa-PDT and HSV1-TK/GCV gene therapy on prostate cancer. Lasers Med Sci. 2018; 33(2):227-232. DOI: 10.1007/s10103-017-2331-6. View

10.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

11.

Cramer J, Burtness B, Le Q, Ferris R . The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019; 16(11):669-683. DOI: 10.1038/s41571-019-0227-z. View

12.

Bairoch A . The Cellosaurus, a Cell-Line Knowledge Resource. J Biomol Tech. 2018; 29(2):25-38. PMC: 5945021. DOI: 10.7171/jbt.18-2902-002. View

13.

Ang K, Berkey B, Tu X, Zhang H, Katz R, Hammond E . Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002; 62(24):7350-6. View

14.

Ribeiro I, Rodrigues J, Mascarenhas A, Kosyakova N, Caramelo F, Liehr T . Cytogenetic, genomic, and epigenetic characterization of the HSC-3 tongue cell line with lymph node metastasis. J Oral Sci. 2018; 60(1):70-81. DOI: 10.2334/josnusd.16-0811. View

15.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

16.

Matsui T, Ota T, Ueda Y, Tanino M, ODASHIMA S . Isolation of a highly metastatic cell line to lymph node in human oral squamous cell carcinoma by orthotopic implantation in nude mice. Oral Oncol. 1998; 34(4):253-6. View

17.

Eccles S, Welch D . Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007; 369(9574):1742-57. PMC: 2214903. DOI: 10.1016/S0140-6736(07)60781-8. View

18.

Pulley J, Jerome R, Ogletree M, Bernard G, Lavieri R, Zaleski N . Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program. Target Oncol. 2017; 13(1):61-68. PMC: 5826865. DOI: 10.1007/s11523-017-0542-1. View

19.

Momose F, Araida T, Negishi A, Ichijo H, Shioda S, Sasaki S . Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J Oral Pathol Med. 1989; 18(7):391-5. DOI: 10.1111/j.1600-0714.1989.tb01570.x. View

20.

Gonzalez-Garcia R, Naval-Gias L, Roman-Romero L, Sastre-Perez J, Rodriguez-Campo F . Local recurrences and second primary tumors from squamous cell carcinoma of the oral cavity: a retrospective analytic study of 500 patients. Head Neck. 2009; 31(9):1168-80. DOI: 10.1002/hed.21088. View